Boston Scientific (BSX) slips Friday after acknowledging in a regulatory filing late Thursday receipt of a subpoena from the U.S. Health and Human Services department related to the drugmaker’s Cognis and Teligen line of defibrillator devices.
The subpoena, received May 5, requested information related to the 2008 launch of two brands of implanted cardiac defibrillators, or ICDs, made by Boston Scientific, the company said. The subpoena also sought information related to the performance of the devices between 2007 and 2009, and the operation of a “Physician Guided Learning Program,” the filing said.
Boston Scientific said it is cooperating with the request.
The company had total net sales of $7.14 billion last year for defibrillators and other implanted heart devices including pacemakers and stents, which prop open narrowed or weakened arteries.
Latest posts by Richard Carlisle (see all)
- Yes, Science Made Low-Fat Bacon Possible (Study) - Oct 31, 2017
- Scientists Report Success In Experimental Therapy To Prevent Zika - Oct 5, 2017
- A Paper-Based Test Can Seemingly Detect Zika In A Matter Of Minutes - Sep 29, 2017